FeesSafety
Pluang+

Nanobiotix reports promising Phase 1 results for JNJ-1900 in resistant melanoma with 41.7% response rate

Company Fundamentals
24 Oct 2026
GlobeNewsWire
View Source
Bullish
Nanobiotix reports promising Phase 1 results for JNJ-1900 in resistant melanoma with 41.7% response rate

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3) combined with immune checkpoint inhibitors in 24 patients with advanced primary cutaneous melanoma resistant to anti-PD-1 therapy. The treatment showed a 41.7% overall response rate, including complete responses, and a median overall survival of 17.8 months, surpassing typical outcomes in this difficult-to-treat group. The therapy was well tolerated and triggered immune activation, suggesting potential for further development. These findings support advancing to randomized clinical trials to better evaluate efficacy and safety.

Nanobiotix Phase 1 trial results provide context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 24, 2026 14:41 WIB: Of 150 priced US health-sector stocks, 44 rose and 105 fell. Notable movers include HIMS at USD 27.71 (-4.87%), AMLX at USD 27.20 (-4.80%), and TVTX at USD 50.05 (-4.54%). Typical hold times range from 9 to 22 days, with HIMS showing 74% sell activity on Pluang.

More News

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
14 minutes ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
14 minutes ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
2 hours ago
NEAR Protocol to hold Q3 Backers Summit on Oct 28 covering tokenomics, AI, and House of Stake proposal.

NEAR Protocol to hold Q3 Backers Summit on Oct 28 covering tokenomics, AI, and House of Stake proposal.

NEAR Protocol announced a Q3 Backers Summit scheduled for October 28. The event will focus on discussions about its House of Stake issuance proposal, updates on NEAR AI, and integration plans. Tokenomics and AI are key topics, with special guests exp...

Protocol Fundamentals
Neutral
4 hours ago
XRP burn rate jumps 75%, signaling stronger network activity and bullish price outlook

XRP burn rate jumps 75%, signaling stronger network activity and bullish price outlook

XRP's network activity has surged, with over 1,114 XRP burned in 24 hours, marking a 27.5% increase from the previous day and the highest daily burn in over two weeks. This rise in burn rate reflects increased transaction activity on the XRP Ledger, ...

Technical Signals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App